Keytruda aids Merck's Q1 performance with $8B in sales. New indications plus combo therapies could fuel the drug's overall growth through 2026.

Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the ...

Erasca (ERAS) on Monday announced a clinical trial collaboration and supply agreement (CTCSA) with Merck (MRK), known as MSD ...

Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck’s KEYTRUDA ...

(Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today ...

Mounjaro surpasses Keytruda top sales with $8.7B in Q1 2025, marking a 125% increase for Eli Lilly over Merck's cancer drug.

One day after a double-pronged loss in prostate and lung cancer, Merck & Co.’s immuno-oncology superstar Keytruda is bouncing back. In the phase 3 Keynote-671 study, Keytruda hit one of two primary ...

Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro has surpassed Merck & Co.’s cancer therapy Keytruda as the world’s ...

Major trial boost: Phase 2 data showed INBRX-106 plus Keytruda doubled response rates in high PD-L1 head and neck cancer patients. Deeper tumor shrinkage: Most responders in the combo arm had over 50% ...

Keytruda is a brand-name biologic drug prescribed to treat certain cancers in adults and some children. Keytruda is given as an intravenous (IV) infusion, which is an injection given into a vein over ...

Merck & Co., Inc. (NYSE:MRK) is a global health care company working to deliver innovative health solutions through our ...